Digistain®

Digistain® email format

Verified email-pattern data for Digistain® is currently limited. You can still use the company insights and contact sections below.
Digistain ® - Leading digital transformation in cancer diagnostics - radically faster gold standard risk scoring analytics at a dramatically lower cost A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), DIGISTAIN® is a patented risk profiling test for hormone receptor-positive breast cancer patients. Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required. The MHRA approved DIGISTAIN technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain.

Company Details

Employees
22
Address
Unit 101, Interchange Business Park,, Howard Way,united Kingdom
Industry
Biotechnology Research
HQ
Newport Pagnell,
Looking for a particular Digistain® employee's phone or email?

Digistain® Questions

Explore related pages

Related company profiles:

Top Digistain® Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant